News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL April 29, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following EUR > 10 million Private Placement and conversion notice from NEGMA EN NL March 30, 2022
News Regulated Transparency/Denominator Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG EN NL March 17, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL February 22, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL December 30, 2021
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL November 30, 2021
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices NEGMA EN NL November 3, 2021
News Regulated Transparency/Denominator Regulated information – Transparency Statement OXUR shares EN NL May 10, 2019
News Regulated Transparency/Denominator Regulated information – Transparency Statement Clay EN NL May 10, 2019
News Regulated Transparency/Denominator Regulated Information / Transparency Statement EN NL April 27, 2018
News Regulated Transparency/Denominator NOVARTIS PHARMA AG HOLDING 5.69% OF THROMBOGENICS EQUITY CAPITAL EN NL January 26, 2018
